# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Viatris Inc. (NASDAQ:VTRS, ", Viatris", or the ", Company", )))) announced today the pricing terms of the previ...
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva,...
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and gl...
The ACT-333441 study was accepted as a late-breaking abstract and was presented during an oral presentation at the 26th Asia-Pa...
Viatris reports Q2 revenue of $3.78 billion, with strong growth in Greater China and new product launches driving results. Adju...